Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4277636 | 1.00 | TDP1 (0.33) | TDP1OPRL1L3MBTL3 | |
| SCHEMBL4575110 | 1.00 | TDP1 (0.33) | TDP1OPRL1L3MBTL3 | |
| Hydrochloric Acid SCHEMBL10326141 | 0.97 | TDP1 (0.32) | TDP1OPRL1 | |
| Hydrochloric Acid SCHEMBL628075 | 0.97 | TDP1 (0.32) | TDP1OPRL1 | |
| Hydrochloric Acid SCHEMBL13583563 | 0.97 | TDP1 (0.32) | TDP1OPRL1 | |
| Hydrochloric Acid SCHEMBL15191249 | 0.97 | TDP1 (0.32) | TDP1OPRL1 | |
| Water SCHEMBL28597949 | 0.97 | TDP1 (0.32) | TDP1OPRL1 | |
| SCHEMBL7795040 | 0.85 | — | — | |
| SCHEMBL661220 | 0.83 | TDP1 (0.42) | TDP1L3MBTL3 | |
| SCHEMBL613375 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 449 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4415816-B1 | PYRROLO[2,1-F][1,2,4]TRIAZINES DERIVATIVES AS INHIBITORS OF DYRK1A | BIOSPLICE THERAPEUTICS INC (US) | 2026-03-18 | — | — | EP | claimed |
| CN-118284610-A | Pyrazolotriazine derivatives as CDK9 inhibitors | 原真股份有限公司 | 2024-07-02 | — | — | CN | claimed |
| WO-2023138204-A1 | PREPARATION METHOD FOR SSZ-16 COPPER-CONTAINING CATALYST | 天津派森新材料技术有限责任公司 | 2023-07-27 | — | — | WO | claimed |
| CN-114210363-A | Preparation method of SSZ-16 copper-containing catalyst | 天津派森新材料技术有限责任公司 | 2022-03-22 | — | — | CN | claimed |
| CN-113462375-A | Chemical intervention in-situ emulsification system | 西南石油大学 | 2021-10-01 | — | — | CN | claimed |
| EP-2794711-B1 | HYDROXY AMINOPOLYMERS AND METHOD FOR THERE MANUFACTURE | COVESTRO DEUTSCHLAND AG (DE) | 2020-06-10 | — | — | EP | claimed |
| US-8946438-B2 | Benzamides, production thereof, and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-03 | — | — | US | claimed |
| EP-2782658-A1 | USE OF CYCLIC AMINES FOR REVERSIBLE ABSORPTION OF CO2 | Büttner, Hermann (DE) | 2014-10-01 | — | — | EP | claimed |
| US-20140187539-A1 | NOVEL BENZAMIDES, PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-03 | — | — | US | claimed |
| US-8735579-B2 | Benzamides, production thereof, and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-27 | — | — | US | claimed |
| EP-0839125-A4 | NOVEL CATIONIC LIPIDS AND THE USE THEREOF | IMARX PHARMACEUTICAL CORP (US) | 2002-10-30 | — | — | EP | claimed |
| CN-1064362-C | Pyrimido [5,4-D] pyrimidines, medicaments containing these compounds, their use and process for their production | THOMAE GMBH DR K (DE) | 2001-04-11 | — | — | CN | claimed |
| CN-1212694-A | Pyrimido [5,4-D] pyrimidines, medicaments containing these compounds, their use and process for their production | THOMAE GMBH DR K (DE) | 1999-03-31 | — | — | CN | claimed |
| US-5821240-A | ENZYME INHIBITORS, SIGNAL INHIBITORS FOR ANTIINFLAMMATORY AGENTS, ANTICARCINOGENIC AGENTS, ANTITUMOR AGENTS AND HORMONE INHIBITORS | DR. KARL THOMAE GMBH (DE) | 1998-10-13 | — | — | US | claimed |
| EP-0614664-B1 | Quinolonecarboxylic acid derivatives, their preparation and their use as cell adhesion inhibitors | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1998-09-16 | — | — | EP | claimed |
| EP-0839125-A1 | NOVEL CATIONIC LIPIDS AND THE USE THEREOF | IMARX PHARMACEUTICAL CORP. (US) | 1998-05-06 | — | — | EP | claimed |
| WO-1996026179-A1 | NOVEL CATIONIC LIPIDS AND THE USE THEREOF | IMARX PHARMACEUTICAL CORP. (US) | 1996-08-29 | — | — | WO | claimed |
| US-5519024-A | CELL ADHESION INHIBITOR | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-05-21 | — | — | US | claimed |
| EP-0227043-A2 | Composite semipermeable membrane and process for producing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1987-07-01 | — | — | EP | claimed |
| US-3944552-A | VULCANIZATION | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 1976-03-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187539-A1 | NOVEL BENZAMIDES, PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS | HRH2, HRH1, HRH4 | TDP1 3840/4885OPRL1 873/4885L3MBTL3 4439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.